COVIFOR is authorized for use under EUA for treatment of patients hospitalized with suspected or laboratory confirmed SARS-CoV-2 infection and severe disease. Remdesivir is a nucleotide analog with broad spectrum antiviral activity and is approved by Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA). Also, Drug controller General of India (DCGI) approved remdesivir for emergency use for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. Remdesivir may have a potential activity against COVID-19 on basis of the in vitro and in vivo activity in animal models against the viral pathogens MERS and SARS, which are also coronaviruses and are structurally similar to COVID-19.
Day 1: Two doses of 100 mg injection of COVIFOR (Remdesivir Injection)
Day 2-5: Single dose of 100 mg daily
Covifor Injection is used in the treatment of hospitalized Coronavirus disease (COVID-19) patients.